Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01235468 | Allogenic Transplantation of Ex-vivo Expanded Cord Blood (CB) | withdrawn | Phase 1 | 0 | Dr. Avichai Shimoni MDOTHER_GOV | 0 | Dec 3, 2015 | clinicaltrials |
| NCT00578045 | UARK 2006-28 Human Cord Blood Transplantation in Advanced Hematological Malignancies | withdrawn | Phase 1 | 0 | University of ArkansasOTHER | 1 | Oct 26, 2015 | clinicaltrials |
| NCT01180569 |
| Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma |
| withdrawn |
| Phase 1 / Phase 2 |
| 0 |
| Memorial Sloan Kettering Cancer CenterOTHER |
| 0 |
| Sep 25, 2015 |
| clinicaltrials |
| NCT01490047 | Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas | withdrawn | Phase 1 | 0 | Ludwig Institute for Cancer ResearchOTHER | 1 | Jun 16, 2015 | clinicaltrials |
| NCT01188889 | RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease. | withdrawn | Phase 1 / Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 15, 2015 | clinicaltrials |
| NCT00024115 | BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Apr 28, 2015 | clinicaltrials |
| NCT00092274 | Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | GlaxoSmithKlineINDUSTRY | 1 | Apr 21, 2015 | clinicaltrials |
| NCT00093314 | HuMax-CD20 in Chronic Lymphocytic Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | GlaxoSmithKlineINDUSTRY | 1 | Apr 21, 2015 | clinicaltrials |
| NCT01065545 | The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Northwestern UniversityOTHER | 0 | Apr 10, 2015 | clinicaltrials |
| NCT00210340 | A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis | withdrawn | Phase 1 | 0 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 0 | Mar 30, 2015 | clinicaltrials |
| NCT00002790 | Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant | withdrawn | Phase 1 / Phase 2 | 0 | Fred Hutchinson Cancer CenterOTHER | 0 | Mar 6, 2015 | clinicaltrials |
| NCT00516191 | A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma(DMV) | withdrawn | Phase 1 / Phase 2 | 0 | University of California, San FranciscoOTHER | 1 | Mar 4, 2015 | clinicaltrials |
| NCT02238522 | Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML | withdrawn | Phase 1 | 0 | Zenith EpigeneticsINDUSTRY | 1 | Nov 13, 2014 | clinicaltrials |
| NCT02115035 | A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib | withdrawn | Phase 1 / Phase 2 | 0 | University of ArkansasOTHER | 1 | Aug 27, 2014 | clinicaltrials |
| NCT02095574 | A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma | withdrawn | Phase 1 | 0 | AbbVieINDUSTRY | 0 | Aug 13, 2014 | clinicaltrials |
| NCT00458744 | Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment | withdrawn | Phase 1 | 0 | Children's Oncology GroupNETWORK | 0 | Aug 8, 2014 | clinicaltrials |
| NCT01969682 | A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199 | withdrawn | Phase 1 | 0 | AbbVieINDUSTRY | 1 | May 26, 2014 | clinicaltrials |
| NCT01620229 | Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 21, 2014 | clinicaltrials |
| NCT00521261 | Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | withdrawn | Phase 1 | 0 | Barbara Ann Karmanos Cancer InstituteOTHER | 0 | Mar 5, 2014 | clinicaltrials |
| NCT00866346 | PR1-Specific Cytotoxic T-Lymphocyte Infusion With Recurrent Chronic Myelogenous Leukemia (CML) After Allogeneic Hematopoietic Transplantation | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Mar 4, 2014 | clinicaltrials |
| NCT00396968 | AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS | withdrawn | Phase 1 / Phase 2 | 0 | Genzyme, a Sanofi CompanyINDUSTRY | 0 | Feb 11, 2014 | clinicaltrials |
| NCT01251250 | Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 0 | Jan 13, 2014 | clinicaltrials |
| NCT01478074 | ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Altor BioScienceINDUSTRY | 1 | Jan 3, 2014 | clinicaltrials |
| NCT00129558 | A Study to Evaluate PT-523 in Patients With Refractory Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00957320 | Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL) | withdrawn | Phase 1 | 0 | Emory UniversityOTHER | 1 | Dec 3, 2013 | clinicaltrials |
| NCT00297921 | A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy | withdrawn | Phase 1 / Phase 2 | 0 | Millennium Pharmaceuticals, Inc.INDUSTRY | 0 | Nov 6, 2013 | clinicaltrials |
| NCT00457574 | Safety and Efficacy of GMX1777 in the Treatment of Refractory Solid Tumors or Lymphomas | withdrawn | Phase 1 | 0 | Gemin XINDUSTRY | 0 | Aug 28, 2013 | clinicaltrials |
| NCT00829205 | Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment | withdrawn | Phase 1 / Phase 2 | 0 | Cancer Research UKOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT00872976 | Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia | withdrawn | Phase 1 | 0 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 22, 2013 | clinicaltrials |
| NCT00776802 | GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma(GCS-100LE) | withdrawn | Phase 1 / Phase 2 | 0 | La Jolla Pharmaceutical CompanyINDUSTRY | 1 | Jun 25, 2013 | clinicaltrials |
| NCT01238146 | Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2013 | clinicaltrials |
| NCT00968461 | Study of Phenethyl Isothiocyanate in Lymphoproliferative Disorders | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Apr 15, 2013 | clinicaltrials |
| NCT00030355 | Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Mar 22, 2013 | clinicaltrials |
| NCT00003435 | Antiviral Therapy Plus Either Peripheral Stem Cell or Umbilical Cord Blood Transplantation in Treating Patients Who Are HIV Positive and Have Hematologic Cancer | withdrawn | Phase 1 | 0 | Duke UniversityOTHER | 1 | Mar 7, 2013 | clinicaltrials |
| NCT01680796 | Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma | withdrawn | Phase 1 | 0 | University of FloridaOTHER | 0 | Feb 20, 2013 | clinicaltrials |
| NCT01101412 | Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Feb 15, 2013 | clinicaltrials |
| NCT01568632 | Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Nov 21, 2012 | clinicaltrials |
| NCT00002761 | Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Columbia UniversityOTHER | 0 | Nov 19, 2012 | clinicaltrials |
| NCT00972101 | Infusion of Expanded Cord Blood T Cells | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Oct 11, 2012 | clinicaltrials |
| NCT00962715 | Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Aug 3, 2012 | clinicaltrials |
| NCT01168882 | Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies | withdrawn | Phase 1 | 0 | AgennixINDUSTRY | 0 | Aug 2, 2012 | clinicaltrials |
| NCT00800566 | Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL) | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 1, 2012 | clinicaltrials |
| NCT00939172 | TTP607 in Refractory Solid Malignancies | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jul 31, 2012 | clinicaltrials |
| NCT01139359 | Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma | withdrawn | Phase 1 | 0 | Alaunos TherapeuticsINDUSTRY | 0 | Jul 19, 2012 | clinicaltrials |
| NCT00886496 | Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia | withdrawn | Phase 1 | 0 | Enzon Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 20, 2012 | clinicaltrials |
| NCT01452334 | Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy | withdrawn | Phase 1 | 0 | Bristol-Myers SquibbINDUSTRY | 0 | Feb 23, 2012 | clinicaltrials |
| NCT01456182 | Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia | withdrawn | Phase 1 | 0 | Afexa Life Sciences IncINDUSTRY | 1 | Jan 25, 2012 | clinicaltrials |
| NCT01194193 | Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours | withdrawn | Phase 1 | 63 | AstraZenecaINDUSTRY | 0 | May 16, 2011 | clinicaltrials |
| NCT00162513 | Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | — | Hadassah Medical OrganizationOTHER | 1 | Apr 28, 2011 | clinicaltrials |
| NCT01170052 | Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL) | withdrawn | Phase 1 / Phase 2 | 20 | Charite University, Berlin, GermanyOTHER | 1 | Mar 16, 2011 | clinicaltrials |
Data updated 23 days agoSource updated Dec 3, 2015source: clinicaltrials